Mechanistically, ARL5B overexpression robustly activated fatty acid metabolic pathways, particularly those involving key enzymes such as SCD1, ACLY, and FASN, confirming its role in fueling ESCC malignancy through lipid biosynthesis. Here, ARL5B is linked to esophageal squamous cell carcinoma.